The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.
 
Kaoru Tsuchiya
Consulting or Advisory Role - Bayer; Eisai
Speakers' Bureau - Bayer; Eisai
 
Masayuki Kurosaki
Consulting or Advisory Role - Abbvie; Bayer; Eisai; Gilead Sciences; Otsuka; Shionogi
Speakers' Bureau - Abbott; Abbvie; Bayer; Eisai; Gilead Sciences; Otsuka; Shionogi
 
Hiroyuki Marusawa
No Relationships to Disclose
 
Takehiko Abe
No Relationships to Disclose
 
CHIKARA OGAWA
No Relationships to Disclose
 
Tetsuro Sohda
No Relationships to Disclose
 
Hiroyuki Kimura
No Relationships to Disclose
 
Masahiko Kondo
No Relationships to Disclose
 
Keiji Tsuji
No Relationships to Disclose
 
Koichiro Furuta
No Relationships to Disclose
 
Masaya Shigeno
No Relationships to Disclose
 
Kouji Joko
No Relationships to Disclose
 
Ryoichi Narita
No Relationships to Disclose
 
Yasushi Uchida
No Relationships to Disclose
 
Hideo Yoshida
No Relationships to Disclose
 
Takehiro Akahane
No Relationships to Disclose
 
Haruhiko Kobashi
No Relationships to Disclose
 
Akeri Mitsuda
No Relationships to Disclose
 
Yuji Kojima
No Relationships to Disclose
 
Namiki Izumi
Consulting or Advisory Role - Bayer; Eisai
Speakers' Bureau - Abbvie; Bayer; Eisai; Gilead Sciences; Otsuka